Peptide record

TPDB06824

Antibacterial Anticancer Antifungal Toxicity standard
12 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB06824
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifungipept CAFPdb dbAMP
standard
No
A 12-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, AntiCP 2.0, and other sources, with an available 3D structural model.
Sequence
AKRHHGYKRKFH
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C71H109N27O14
NDCEQILMPSTWV
HK
1564.82
11.59
8
0
3
+5
4.57
-2.283
8.33
Mammalian: 4.4 hour Yeast: >20 hour E.coli: >10 hour
1490
0.95
1
Residue Composition
number
1
A
2
R
0
N
0
D
0
C
0
E
0
Q
1
G
3
H
0
I
0
L
3
K
0
M
1
F
0
P
0
S
0
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 1 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 3 I: 0 L: 0 K: 3 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 1 V: 0
Chemical Descriptors
12 reviewed residue count
C71H109N27O14 sequence-only estimate (linear, free termini)
1564.82 sequence-only estimate (linear, free termini)
11.59 sequence-only estimate (linear, free termini)
+5 sequence-only estimate (linear, free termini)
4.57 sequence-only estimate (linear, free termini)
-2.283 sequence-only estimate (linear, free termini)
Evidence Records 16 records
Evidence 1 Activity

Activity

MIC
Antibacterial
0.78-12.5 µg/mL

Target

C. albican ATCC MYA-2876 or ATCC 90028 or 3 more from patients

Source & Reference

dbAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class.
ctive against C. albicans (LD50 2.3 ug/ml LD90 4.7 ug/ml). Also active against 5 strains C. albican ATCC MYA-2876 or ATCC 90028 or 3 more from patients (MIC 0.78-12.5 ug/ml), C-glabrata ATCC 9003 (MIC >50 ug/ml), C. krusei ATCC 6258 or HIV patient (MIC 6.25-12.5
Evidence 2 Activity

Activity

MIC
Antibacterial
6.25-12.5 µg/mL

Target

C. krusei ATCC 6258 or HIV patient

Source & Reference

dbAMP

Other

0028 or 3 more from patients (MIC 0.78-12.5 ug/ml), C-glabrata ATCC 9003 (MIC >50 ug/ml), C. krusei ATCC 6258 or HIV patient (MIC 6.25-12.5 ug/ml), C. parapsilosis ATCC 22019 (MIC 0.78 ug/ml), C. tropicalis ATCC 13803 and 3 strains HIV
Evidence 3 Activity

Activity

MIC
Antibacterial
0.78 µg/mL

Target

C. parapsilosis ATCC 22019

Source & Reference

dbAMP

Other

rata ATCC 9003 (MIC >50 ug/ml), C. krusei ATCC 6258 or HIV patient (MIC 6.25-12.5 ug/ml), C. parapsilosis ATCC 22019 (MIC 0.78 ug/ml), C. tropicalis ATCC 13803 and 3 strains HIV patient (MIC 0.78-1.56 ug/ml), C. dubliniensi
Evidence 4 Activity

Activity

MIC
Antibacterial
0.78-1.56 µg/mL

Target

C. tropicalis ATCC 13803 and HIV patient

Source & Reference

dbAMP

Other

C 6258 or HIV patient (MIC 6.25-12.5 ug/ml), C. parapsilosis ATCC 22019 (MIC 0.78 ug/ml), C. tropicalis ATCC 13803 and 3 strains HIV patient (MIC 0.78-1.56 ug/ml), C. dubliniensis HIV patient (MIC 6.25 ug/ml), C. glabrata HIV patient (MIC 25 ug/ml). Bo
Evidence 5 Activity

Activity

MIC
Antibacterial
6.25 µg/mL

Target

C. dubliniensis HIV patient

Source & Reference

dbAMP

Other

IC 0.78 ug/ml), C. tropicalis ATCC 13803 and 3 strains HIV patient (MIC 0.78-1.56 ug/ml), C. dubliniensis HIV patient (MIC 6.25 ug/ml), C. glabrata HIV patient (MIC 25 ug/ml). Both the D and L forms (D=L) were equally active
Evidence 6 Activity

Activity

MIC
Antibacterial
25 µg/mL

Target

C. glabrata HIV patient

Source & Reference

dbAMP

Other

strains HIV patient (MIC 0.78-1.56 ug/ml), C. dubliniensis HIV patient (MIC 6.25 ug/ml), C. glabrata HIV patient (MIC 25 ug/ml). Both the D and L forms (D=L) were equally active against C. albicans, but only the D-for
Evidence 7 Activity

Activity

MIC
Antifungal
0.78-12.5 µg/mL

Target

C. albican ATCC MYA-2876 or ATCC 90028 or 3 more from patients

Source & Reference

dbAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class.
ctive against C. albicans (LD50 2.3 ug/ml LD90 4.7 ug/ml). Also active against 5 strains C. albican ATCC MYA-2876 or ATCC 90028 or 3 more from patients (MIC 0.78-12.5 ug/ml), C-glabrata ATCC 9003 (MIC >50 ug/ml), C. krusei ATCC 6258 or HIV patient (MIC 6.25-12.5
Evidence 8 Activity

Activity

MIC
Antifungal
6.25-12.5 µg/mL

Target

C. krusei ATCC 6258 or HIV patient

Source & Reference

dbAMP CAFPdb Antifungipept

Other

0028 or 3 more from patients (MIC 0.78-12.5 ug/ml), C-glabrata ATCC 9003 (MIC >50 ug/ml), C. krusei ATCC 6258 or HIV patient (MIC 6.25-12.5 ug/ml), C. parapsilosis ATCC 22019 (MIC 0.78 ug/ml), C. tropicalis ATCC 13803 and 3 strains HIV
Evidence 9 Activity

Activity

MIC
Antifungal
0.78 µg/mL

Target

C. parapsilosis ATCC 22019

Source & Reference

dbAMP CAFPdb Antifungipept

Other

rata ATCC 9003 (MIC >50 ug/ml), C. krusei ATCC 6258 or HIV patient (MIC 6.25-12.5 ug/ml), C. parapsilosis ATCC 22019 (MIC 0.78 ug/ml), C. tropicalis ATCC 13803 and 3 strains HIV patient (MIC 0.78-1.56 ug/ml), C. dubliniensi
Evidence 10 Activity

Activity

MIC
Antifungal
0.78-1.56 µg/mL

Target

C. tropicalis ATCC 13803 and HIV patient

Source & Reference

dbAMP CAFPdb Antifungipept

Other

C 6258 or HIV patient (MIC 6.25-12.5 ug/ml), C. parapsilosis ATCC 22019 (MIC 0.78 ug/ml), C. tropicalis ATCC 13803 and 3 strains HIV patient (MIC 0.78-1.56 ug/ml), C. dubliniensis HIV patient (MIC 6.25 ug/ml), C. glabrata HIV patient (MIC 25 ug/ml). Bo
Evidence 11 Activity

Activity

MIC
Antifungal
6.25 µg/mL

Target

C. dubliniensis HIV patient

Source & Reference

dbAMP CAFPdb Antifungipept

Other

IC 0.78 ug/ml), C. tropicalis ATCC 13803 and 3 strains HIV patient (MIC 0.78-1.56 ug/ml), C. dubliniensis HIV patient (MIC 6.25 ug/ml), C. glabrata HIV patient (MIC 25 ug/ml). Both the D and L forms (D=L) were equally active
Evidence 12 Activity

Activity

MIC
Antifungal
25 µg/mL

Target

C. glabrata HIV patient

Source & Reference

dbAMP CAFPdb Antifungipept

Other

strains HIV patient (MIC 0.78-1.56 ug/ml), C. dubliniensis HIV patient (MIC 6.25 ug/ml), C. glabrata HIV patient (MIC 25 ug/ml). Both the D and L forms (D=L) were equally active against C. albicans, but only the D-for
Evidence 13 Activity

Activity

1% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
1% Hemolysis | 100 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
In vitro synergic antifungal effect of MUC7 12-mer with histatin-5 12-mer or miconazole. | J Antimicrob Chemother | 2004
Evidence 14 Activity

Activity

50% Hemolysis
Toxicity
>192 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | >192 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
The Antimicrobial Peptides P-113Du and P-113Tri Function against Candida albicans. | Antimicrob Agents Chemother | 2016
Evidence 15 Activity

Activity

0% Hemolysis
Toxicity
50 µg/mL
Hemolytic Cytotoxic
0% Hemolysis | 50 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Dependence on size and shape of non-nature amino acids in the enhancement of lipopolysaccharide (LPS) neutralizing activities of antimicrobial peptides. | J Colloid Interface Sci | 2019
Evidence 16 Activity

Activity

Toxicity
Cytotoxic
- | NA | target cell: Human fibroblasts

Target

Human fibroblasts

Source & Reference

NA
DBAASP
Dependence on size and shape of non-nature amino acids in the enhancement of lipopolysaccharide (LPS) neutralizing activities of antimicrobial peptides. | J Colloid Interface Sci | 2019